Corcept Therapeutics (CORT) Total Current Liabilities (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Total Current Liabilities data on file, last reported at $149.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 4.28% year-over-year to $149.2 million; the trailing twelve-month figure through Mar 2026 stood at $149.2 million (up 4.28% YoY), and the FY2025 full-year result was $166.1 million, up 17.98% from the prior year.
• Total Current Liabilities slipped to $149.2 million in Q1 2026, from $166.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $172.3 million in Q3 2025 to a low of $49.1 million in Q2 2022.
• A 5-year average of $110.0 million and a median of $104.5 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities jumped 129.65% in 2023 and advanced 3.56% in 2024, its largest moves.
• Tracing CORT's Total Current Liabilities over 5 years: stood at $72.5 million in 2022, then surged by 44.16% to $104.5 million in 2023, then soared by 34.7% to $140.8 million in 2024, then gained by 17.98% to $166.1 million in 2025, then dropped by 10.18% to $149.2 million in 2026.
• Business Quant data shows CORT's Total Current Liabilities at $149.2 million in Q1 2026, $166.1 million in Q4 2025, and $172.3 million in Q3 2025.